HopeStage
Back to all studies
TerminatedNCT05329779

Study on Allopregnanolone and Depression in Perimenopausal Women

Medication studyAges 40–60United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 40 years to 60 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 4, 2022
Recruitment status
Terminated
Enrollment listed in the registry
2
Sponsor
Brigham and Women's Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 40 Years to 60 Years
Official registry ID
NCT05329779
Official title
Show the full official title

Using Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women During the Perimenopause

Recruitment & locations

Terminated

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Brigham and Women's Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including brexanolone and placebo.

Who can participate?

Listed age limits: 40 years to 60 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies